Rigel Pharmaceuticals, Inc. (RIGL) vs SL Science Holding Ltd (SLBT)
A side-by-side comparison of Rigel Pharmaceuticals, Inc. and SL Science Holding Ltd across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
RIGL
Rigel Pharmaceuticals, Inc.
$46.57HealthcareDelayed quote: Oct 6, 2026, 2:14 PM EDT
SLBT
SL Science Holding Ltd
$1.52HealthcareDelayed quote: Oct 6, 2026, 2:08 PM EDT
Total return — RIGL vs SLBT
growth of $100 · dividends reinvested · last 1yRIGL +62.7% (+62.7%/yr)SLBT -79.6% (-79.6%/yr)RIGL compounded faster over this window
Log scale — wide-divergence pair
RIGL SLBT
RIGL vs SLBT: by the numbers
- •RIGL is the larger company ($862M vs $853M market cap).
- •RIGL is profitable (116.30% net margin) while SLBT runs a net loss (-173.85%).
Metrics side by side
Valuation
| Metric | RIGL | SLBT |
|---|---|---|
| P/E ratio | 2.85 | N/A |
| Forward P/E | 13.58 | N/A |
| P/S ratio | 3.11 | N/A |
| P/B ratio | 2.03 | 373.57 |
| EV / EBITDA | 9.37 | N/A |
| FCF yield | 9.21% | N/A |
Profitability
| Metric | RIGL | SLBT |
|---|---|---|
| Gross margin | 91.39% | 35.27% |
| Operating margin | 42.63% | -174.65% |
| Net margin | 116.30% | -173.85% |
| ROE | 75.67% | -167.25% |
| ROIC | 18.72% | -163.39% |
Growth (annualized)
| Metric | RIGL | SLBT |
|---|---|---|
| Revenue CAGR (5Y) | 13.94% | N/A |
| Total return CAGR (5Y) | 6.25% | N/A |
Frequently asked
- Is RIGL or SLBT more profitable?
- RIGL runs the higher net margin — RIGL at 116.30% versus SLBT at -173.85%.
Go deeper
Dig into the metrics
Rigel Pharmaceuticals P/E ratioRigel Pharmaceuticals ROESL Science ROERigel Pharmaceuticals operating marginSL Science operating marginRigel Pharmaceuticals revenue growthSL Science revenue growthRigel Pharmaceuticals free cash flowSL Science free cash flow
Rigel Pharmaceuticals & SL Science appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.